REJUVANAD+ PRO is prepared by reconstituting and diluting the NAD+ 500 mg vial according to the PENMIX instructions for use, then administered as a slow intravenous NAD+ infusion under the supervision of a qualified clinician. A conservative initial rate, adjusted gradually upward, can help establish each patient’s tolerance threshold.

Infusion rate is the main determinant of tolerability. When NAD+ is infused too quickly, patients may experience transient nausea, flushing, or sensations of chest or abdominal tightness. The rate should be titrated to patient tolerance and slowed or paused if these reactions occur.

Nicotinamide adenine dinucleotide is a naturally occurring coenzyme in the NAD+/NADH redox system, supporting cellular energy metabolism and mitochondrial ATP production. NAD+ also acts as a substrate for enzymes including sirtuins and poly(ADP-ribose) polymerases, or PARPs.

While related compounds such as NMN and NR are discussed as NAD+ precursors, REJUVANAD+ PRO delivers nicotinamide adenine dinucleotide IV as an injectable presentation for direct parenteral use. It may be administered within an IV therapy setting at the prescribing clinician’s discretion. Clinical evidence for intravenous NAD+ remains limited, and commonly marketed wellness applications should not be interpreted as established or approved indications. Treatment decisions should be based on professional judgment, applicable regulations, and available clinical evidence.

• Active ingredient: Nicotinamide adenine dinucleotide (NAD+)

• Strength: 500 mg per vial

• Pack content: 1 vial

• Manufacturer: PENMIX Ltd.

• Form/route: Prescription injectable for parenteral, intravenous use

NAD+ is a water-soluble coenzyme that cycles between its oxidized (NAD+) and reduced (NADH) forms to carry electrons in cellular energy metabolism. It also functions as a co-substrate for sirtuins and PARPs.

The standardized 500 mg vial provides a defined quantity of NAD+ for preparation per the manufacturer’s instructions. Regulatory requirements for NAD+ injection products vary by jurisdiction, and practitioners should not assume that compounded preparations carry the same regulatory status or quality controls. The FDA has raised specific concerns about unsuitable ingredients in sterile compounded NAD+ injections. Clinics that buy NAD+ IV therapy supplies wholesale should confirm cold-chain compliance, product traceability, and distributor documentation before accepting delivery.

For practitioners evaluating where to buy NAD+ IV therapy products online, verifying credentials and applicable regulatory requirements is an equally important step. Shipping conditions matter for this product class, since temperature excursions during transit can compromise injectable product integrity. Our team is available to answer product questions from licensed healthcare professionals.

REJUVANAD+ PRO is intended for administration by a licensed healthcare professional within their scope of practice. Reconstitute and dilute the 500 mg vial per the PENMIX instructions for use, then administer via slow IV infusion, titrating the rate to patient tolerance.

Appropriate IV access, patient monitoring, and procedures for managing infusion-related reactions should be in place throughout. If nausea, flushing, chest tightness, or abdominal discomfort develops, slow or temporarily pause the infusion.

Before treatment, assess patient suitability, medical history, and potential contraindications, including hypersensitivity to any product component. Caution is appropriate where safety data are limited, including during pregnancy or breastfeeding. Licensed professionals who purchase NAD+ IV therapy online should verify that shipping and storage conditions were maintained before use. Store REJUVANAD+ PRO according to the manufacturer’s instructions.